EANS-News: Valneva SE / Biological E's Japanese Encephalitis vaccine prequalified by the World Health Organization

CORPORATE NEWS TRANSMITTED BY EURO ADHOC. THE ISSUER/ORIGINATOR IS SOLELY RESPONSIBLE FOR THE CONTENT OF THIS ANNOUNCEMENT.
Joint Ventures/Cooperation/Collaboration

Hyderabad, India / Lyon, France (euro adhoc) - Hyderabad, India / Lyon, France July 22 2013 - Indian Biopharmaceutical company Biological E (BioE) and European biotech company Valneva SE (Valneva) today announced that the World Health Organization (WHO) has awarded prequalification for global use in adults of BioE's Japanese Encephalitis vaccine. This is the first prequalification of a Japanese Encephalitis vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries. BioE also expects the pediatric indication to be prequalified by the end of the year.

Ms Mahima Datla, Managing Director, Biological E Limited said, "We are happy that our JE vaccine is the first ever WHO prequalified JE vaccine. It is an extremely important achievement for the vaccines community as our vaccine's prequalification is well in time to support GAVI's plans of introducing the JE vaccine in several developing countries."

Thomas Lingelbach, Valneva's President and Chief Executive Officer and Franck Grimaud, Valneva's President and Chief Business Officer, also commented, "We share the excitement for this great achievement and are pleased that our technology used for IXIARO® will now help introducing an excellent vaccine in countries of substantial needs." (IXIARO® is an FDA and EMA approved vaccine).

Biological E and Valneva (ex Intercell) established a partnership in 2005 for the development and commercialization of a Japanese encephalitis vaccine for endemic regions, based on Valneva's JEV technology. The vaccine, which was successfully developed under this partnership, is being marketed in India under the trade-name JEEV® and commercialization in other JE-endemic countries is planned.

Biological E has emerged as a fast growing company. It was in the news recently for entering into a five year Pentavalent supply arrangement with GAVI, for forming a Joint Venture with GlaxoSmithKline (GSK) to create a six-in-one paediatric vaccine combining GSK's IPV and BioE's pentavalent vaccine and for licensing Novartis's Phase II Typhoid Conjugate vaccine.

Media contacts
Divya Bijlwan Associate Vice President Strategic Operations and Planning Biological E Limited T +91-40-30214092 Email: divya.bijlwan@biologicale.co.in

Valneva SE Laetitia Bachelot- Fontaine Investor Relations and Communication Manager T +33 2 28 07 37 10 M + 33 6 45 16 70 99 E Communications@valneva.com